Chia-Chi Wang
Overview
Explore the profile of Chia-Chi Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
197
Citations
2168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pan Z, Wei W, Tran P, Fang R, Pham T, Bowman J, et al.
Nat Commun
. 2025 Mar;
16(1):2503.
PMID: 40082396
Helper-component proteinase (HC-Pro), encoded by potyviruses, function as viral suppressors of RNA silencing (VSRs). Despite their conserved role, HC-Pros share approximately 40% similarity, implying potential differences in VSR efficiency, particularly...
2.
Wang H, Zeng Y, Huang C, Chen C, Kuo H, Tseng K, et al.
J Formos Med Assoc
. 2025 Mar;
PMID: 40023754
Purpose: This study investigated whether Fibrosis-4 (FIB-4) score and its change can serve as predictors of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C (CHC) infection receiving direct-acting...
3.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C, et al.
Hepatol Int
. 2025 Feb;
PMID: 40016576
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association...
4.
Wang S, Wang S, Huang C, Chang T, Chang T, Lo C, et al.
Kaohsiung J Med Sci
. 2025 Jan;
41(2):e12929.
PMID: 39829106
An 8-week regimen of glecaprevir/pibrentasvir is recommended for treatment-naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study...
5.
Kan H, Wang S, Liao C, Tsai W, Wang C, Tung C
Toxics
. 2025 Jan;
12(12.
PMID: 39771151
Non-animal assessment of skin sensitization is a global trend. Recently, scientific efforts have been focused on the integration of multiple evidence for decision making with the publication of OECD Guideline...
6.
Wang S, Wang C, Cheng Y, Chen C, Hsieh T, Wang C, et al.
Hepatol Int
. 2025 Jan;
PMID: 39755997
Background/purpose: Although metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed to replace the diagnosis of non-alcoholic fatty liver disease (NAFLD) with new diagnostic criteria since 2023, the genetic predisposition...
7.
Wang S, Chang Y, Wang C, Cheng Y, Hsieh T, Wang C, et al.
World J Hepatol
. 2025 Jan;
16(12):1429-1440.
PMID: 39744191
Background: A new nomenclature of metabolic associated steatotic liver disease (MASLD) was proposed in 2023, thus expanding the diagnostic name of "MASLD combined with other etiologies". Aim: To investigate the...
8.
Cheng Y, Wang S, Wang C, Kao J
Tzu Chi Med J
. 2024 Oct;
36(4):425-432.
PMID: 39421499
Objectives: Metabolic-associated fatty liver disease (MAFLD) was proposed in 2020 to replace the original term nonalcoholic fatty liver disease (NAFLD) with new diagnostic criteria. The disease risks of lean and...
9.
Cheng Y, Hsieh T, Wang C, Kao J
JGH Open
. 2024 Oct;
8(10).
PMID: 39403113
Aims: Metabolic associated fatty liver disease (MAFLD) was proposed to replace "non-alcoholic fatty liver disease (NAFLD) with new diagnostic criteria." The group meeting these two diagnostic criteria is called "Overlapping...
10.
Wang S, Wang C, Wang C, Lin Y, Tung C
J Xenobiot
. 2024 Aug;
14(3):1023-1035.
PMID: 39189172
In silico toxicogenomics methods are resource- and time-efficient approaches for inferring chemical-protein-disease associations with potential mechanism information for exploring toxicological effects. However, current in silico toxicogenomics systems make inferences based...